Centers for Disease Control and Prevention. 2019 Annual surveillance report of drug-related risks and outcomes - United States surveillance special report. Atlanta, GA: Centers for Disease Control and Prevention, HHS. https://www.cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillance-report.pdf. Published November 1, 2019. Accessed April 5, 2021.
Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health (HHS Publication No.PEP21-07-01-003, NSDUH Series H-56). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf. Published October 2021. Accessed December 20, 2021.
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of Preventive MedicineREFERENCES
- CDC guideline for prescribing opioids for chronic pain - United States, 2016 [published correction appears in MMWR Recomm Rep. 2016;65(11):295].MMWR Recomm Rep. 2016; 65: 1-49https://doi.org/10.15585/mmwr.rr6501e1
Centers for Disease Control and Prevention. 2019 Annual surveillance report of drug-related risks and outcomes - United States surveillance special report. Atlanta, GA: Centers for Disease Control and Prevention, HHS. https://www.cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillance-report.pdf. Published November 1, 2019. Accessed April 5, 2021.
Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health (HHS Publication No.PEP21-07-01-003, NSDUH Series H-56). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf. Published October 2021. Accessed December 20, 2021.
- Initial opioid prescriptions among U.S. commercially insured patients, 2012-2017.N Engl J Med. 2019; 380: 1043-1052https://doi.org/10.1056/NEJMsa1807069
- Characteristics of initial prescription episodes and likelihood of long-term opioid use - United States, 2006-2015.MMWR Morb Mortal Wkly Rep. 2017; 66: 265-269https://doi.org/10.15585/mmwr.mm6610a1
CDC file of national drug codes for selected benzodiazepines, muscle relaxants, stimulants, opioid analgesics, and linked oral morphine milligram equivalent conversion factors for opioids. Centers for Disease Control and Prevention. https://www.cdc.gov/opioids/data-resources/index.html. Updated March 24, 2021. Accessed April 12, 2021.
- Prescribing of opioid analgesics and buprenorphine for opioid use disorder during the COVID-19 pandemic.JAMA Netw Open. 2021; 4e216147https://doi.org/10.1001/jamanetworkopen.2021.6147
- National Center for Health Statistics guidelines for analysis of trends.Vital Health Stat 2. 2018; 179: 1-71https://www.cdc.gov/nchs/data/series/sr_02/sr02_179.pdfDate accessed: March 31, 2022
HHS. HHS guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. Washington, DC: HHS. https://www.hhs.gov/opioids/sites/default/files/2019-10/Dosage_Reduction_Discontinuation.pdf. Published October 2019. Accessed February 16, 2021.
